Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Profession Professional Development, Business and Innovation

This month in business

Back when Allergan was trying to avoid takeover by Valeant, they looked at buying the specialist pharmaceutical company, Salix, for US$11 billion. Why? Doing so would wipe out their particularly attractive net cash proportion. It appears that Salix was suffering from inventory issues – wholesalers had amassed too much stock of their biggest-selling products, Uceris, Apriso and Xifaxan. Salix’s Q4 2014 and Q1 2015 sales will therefore have suffered. After their deal with Allergan fell through, Salix was then briefly courted by Actavis – who went on to buy Allergan instead.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register